A PYMNTS Company

US: Russian company can’t sue Roche, Genentech for antitrust violation

By  |  November 6, 2019

Roche, its Genentech subsidiary and an independent Russian distributor cannot be sued in the United States for actions they allegedly took in Russia in order to block a competitor from entering the US market for biosimilar cancer-treatment drugs, a federal appeals court held on Tuesday (November 5). 

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The 2nd US Circuit Court of Appeals rejected Russian pharmaceutical company Biocad JSC’s argument that federal and state antitrust laws are broad enough to cover foreign conduct that is ultimately intended to affect US imports.

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    The suit was filed by Biocad JSC, which makes off-brand versions of cancer medications on which Roche’s patents will soon expire. Biocad also targeted Russian drug distributor R-Pharm JSC and Roche subsidiaries Genentech Inc. and F. Hoffman-La Roche.